Iodine supplementation for children and adolescents improves cognitive function slightly, likely reduces hypothyroidism and infant mortality, and may lower goitre rates, according to data compiled by Cochrane. The intervention uses oral potassium iodide or iodised oil to prevent iodine deficiency disorders in vulnerable populations.
Iodine is an essential mineral that the human body uses to synthesize thyroid hormones. These hormones regulate normal neurological development and physical growth. Without sufficient intake, children face severe risks of intellectual disability and delayed central nervous system development.
Dietary iodine typically comes from iodised salt, seafood, dairy products, and crops grown in iodine-replete soils. When these dietary sources fail, public health initiatives turn to supplementation. Cochrane reported on findings from eight separate studies involving 2,528 participants.
In Plain English: The Clinical Takeaway
- Cognitive Boost: Giving iodine supplements to children at risk of deficiency yields a slight improvement in thinking ability compared to a dummy treatment.
- Thyroid Protection: Supplementation likely causes a substantial drop in hypothyroidism, a condition where the thyroid gland fails to produce enough hormones.
- Infant Survival: In regions suffering from high infant death rates, preventive iodine intake likely reduces mortality from any cause.
The analyzed research spans studies conducted between 1982 and 2009 across low-income environments in countries such as Bangladesh, Albania, Tanzania, and Indonesia. Cochrane evaluated oral iodine supplementation alone or paired with iron against a placebo. These trials assessed developmental markers, physical growth, and disease incidence.
Cognitive assessment data from one trial involving 166 participants showed a slight increase in thinking ability. Three studies measuring weight across 658 children indicated that iodine supplementation results in little to no difference in body weight compared to a placebo. Meanwhile, one study of 264 people demonstrated that iodine administration likely leads to a large reduction in insufficient thyroid hormone production.
Mortality data showed public health benefits in high-risk areas. Cochrane reported that iodine supplementation likely reduces deaths due to any cause, based on a single study of 617 individuals.
Evidence regarding goitre—the abnormal enlargement of the thyroid gland—initially proved uncertain due to methodological flaws in secondary studies. After removing one unverified trial, analysis of a single study involving 230 participants indicated that iodine likely achieves a large reduction in goitre occurrence.
| Clinical Outcome | Intervention vs. Placebo Effect | Participant Count (N) |
|---|---|---|
| Cognitive Function | Slight improvement in thinking ability | 166 |
| Children’s Weight | Little to no difference | 658 |
| Hypothyroidism | Likely large reduction | 264 |
| All-Cause Mortality | Likely reduction in high-mortality areas | 617 |
| Goitre Reduction | Likely large reduction (in vetted data) | 230 |
Combining iodine with iron yielded inconclusive results. Evidence concerning weight changes from one trial of 146 children taking iron and iodine together remained very uncertain. None of the reviewed studies reported unwanted adverse effects or measured quality of life metrics.
Clinical Evidence Varies Due to Unblinding Risks and Demographics
Confidence in the clinical evidence ranges from high to very low across the evaluated endpoints. Limitations stem from unblinding risks where participants or researchers may have known their assigned treatment group. Variations in population demographics and a small total number of trials also restrict broader generalizations.
Cochrane noted that future investigations should target populations where iodine scarcity remains prevalent, explicitly incorporating children from lower socioeconomic strata. Researchers must examine higher doses administered over extended treatment durations and longer follow-up windows.
Clinical Evidence Varies Due to Unblinding Risks and Demographics
Confidence in the clinical evidence ranges from high to very low across the evaluated endpoints. Limitations stem from unblinding risks where participants or researchers may have known their assigned treatment group. Variations in population demographics and a small total number of trials also restrict broader generalizations.
Cochrane noted that future investigations should target populations where iodine scarcity remains prevalent, explicitly incorporating children from lower socioeconomic strata. Researchers must examine higher doses administered over extended treatment durations and longer follow-up windows.
The evidence supporting these findings remains current up to May 2025.
References
- Cochrane Database of Systematic Reviews – Iodine supplementation for preventing iodine deficiency disorders in children and adolescents.
